Breaking immunological tolerance to canine malignant melanoma using anti-Gpnmb antibody and various antigen peptides associated with tumor.

使用抗 Gpnmb 抗体和与肿瘤相关的各种抗原肽打破对犬恶性黑色素瘤的免疫耐受。

• 批准号: 23780317
• 负责人: TOMIHARI Mizuki
• 金额: $ 2.83万
• 依托单位: Obihiro University of Agriculture and Veterinary Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23780317/
• 关键词: 獣医学; 臨床; 癌; 免疫学; 生体分子; 犬; 悪性黒色腫; 免疫療法; 腫瘍; 獣医学; 臨床; 癌; 免疫学; 生体分子; 犬; 悪性黒色腫; 免疫療法; 腫瘍

We investigated new approachof immunological therapy for canine malignant melanoma, using anti-Gpnmb Ab and other various antigen peptides associated with tumor. The research showed that some peptides significantly activated T-lymphocytes compared to conventional method. However, the experiments with anti-Gpnmb Ab did not show notable results in T-cell activation. In the future research, we will thoroughly examine experimental conditions and intend to find more effective immunotherapy.

我们使用抗GPNMB AB和其他与肿瘤相关的各种抗原肽研究了针对犬恶性黑色素瘤的免疫疗法的新方法。研究表明，与常规方法相比，一些肽显着活化的T淋巴细胞。但是，使用抗GPNMB AB的实验在T细胞激活中并未显示出明显的结果。在将来的研究中，我们将彻底检查实验条件，并打算找到更有效的免疫疗法。